



September 9-11 2019

Association of systemic treatments & radiation therapy in breast cancer

Monday, September 9th: Part I : Endocrine treatment and radiation therapy in breast cancer

08:30	REGISTRATION & WELCOME COFFEE		Amphithéâtre Hélène Martel Massignac (BDD) 11-13 rue Pierre & Marie Curie 75005 Paris
08:30 08:45	Pierre Fumoleau Institut Curie - FR	Welcome address.	
08:45 09:30	Elisabetta Marangoni Institut Curie - FR	Preclinical data.	
09:30 10:30	Paul Cottu Institut Curie - FR	The place of endocrine therapy in the multidisciplinary management of breast cancer, including associations with new agents including denosumab and targeted treatments.	
10:30 11:00	BREAK		BDD Hall
11:00 11:30	Etienne Brain Institut Curie - FR	Age and endocrine therapy: does age matter and why?	Amphithéâtre Hélène Martel Massignac (BDD) 11-13 rue Pierre & Marie Curie 75005 Paris
11:30 12:30	Alain Fourquet Institut Curie - FR	Clinical application of endocrine and radiation therapy: concomitant or sequential?	
12:30 13:15	Discussion : all participants	How to optimally associate safely endocrine treatment and radiation therapy?	
13:15 14:00	LUNCH		

Monday, September 9th: Part II : Chemotherapy and radiation therapy in breast cancer

14:00 14:30	Frédérique Mégnin Institut Curie - FR	Preclinical data.	Amphithéâtre Hélène Martel Massignac (BDD) 11-13 rue Pierre & Marie Curie 75005 Paris
14:30 15:15	Jean-Yves Pierga Institut Curie - FR	Current evolutions in chemotherapy in breast cancer treatment: new regimens, evolution of clinical indications, optimal timing, how to take the response to primary systemic therapy into account.	
15:15 15:45	Philip Poortmans Institut Curie - FR	The interaction of chemotherapy and radiation therapy in breast cancer.	
15:45 16:00	Fabien Reyat Institut Curie - FR	Do we need a new trial to introduce preoperative radiation therapy for breast cancer?	
16:00 16:45	Discussion : all participants	How to optimally associate chemotherapy and radiation therapy?	
16:45 19:00	Visit of the Curie Museum & Cocktail		Chez Marie'



September 9-11 2019

Association of systemic treatments & radiation therapy in breast cancer

Tuesday, September 10th: Part III : Targeted treatments and radiation therapy in breast cancer

08:30 09:00	Summary of day 1		
Anti HER2 treatments and radiation therapy			
09:00 09:30	Frédéric Mignot Institut Curie - FR	Preclinical data: how to translate them to future clinical applications?	Amphithéâtre Hélène Martel Massignac (BDD)
09:30 10:15	Martine Piccart Institut Jules Bordet - BE, & Institut Curie - FR	Clinical trials with long term results, what is the next step in adjuvant setting and metastatic settings?	
10:15 10:45	BREAK		BDD HALL
10:45 11:30	Youlia Kirova Institut Curie - FR	Clinical experience of the association of anti-HER2 and radiation therapy. The ESTRO guideline.	Amphithéâtre Hélène Martel Massignac (BDD)
11:30 12:15	Discussion : all participants	How to optimally associate safely anti HER2 and radiation therapy?	
12:15 13:30	LUNCH		
Anti VEGF and radiation therapy			
13:30 14:00	Philippe Beuzeboc Institut Curie - FR	Possible clinical applications of anti VEGF treatment for breast cancer.	Amphithéâtre Hélène Martel Massignac (BDD)
14:00 14:45	Alice Clément-Zhao Institut Curie - FR	Preclinical and clinical data of associating anti VEGF and radiation therapy. Results of the French TOLERAB study.	
14:45 15:15	Discussion : all participants	Can bevacizumab be combined with radiation therapy?	
15:15 15:45	BREAK		BDD HALL
15:45 16:30	François-Clément Bidard Institut Curie - FR	Targeted therapies for breast cancer: what will the next years will bring us?	Amphithéâtre Hélène Martel Massignac (BDD)
16:30 17:30	Discussion : all participants	What's up doc?	



September 9-11 2019

Association of systemic treatments & radiation therapy in breast cancer

Wednesday, September 11th

09:00 09:30	Summary of day 2		
PARP inhibitors and radiation therapy			
09:40 10:00	Frédéric Pouzoulet Institut Curie - FR	Preclinical results of associating PARP inhibitors and radiation therapy.	Amphithéâtre Hélène Martel Massignac (BDD)
10:00 10:30	Delphine Loirat Institut Curie - FR	New clinical developments of PARP inhibitors. The role of BRCA1/2 mutations.	
10:30 11:00	BREAK		BDD HALL
11:00 11:30	Youlia Kirova Institut Curie - FR	Associating PARP inhibitors and radiation therapy in breast cancer: ongoing studies.	Amphithéâtre Hélène Martel Massignac (BDD)
11:30 12:00	Discussion : all participants	How to optimally associate safely PARP inhibitors and radiation therapy?	
12:00 13:00	LUNCH		
Immunotherapy and radiation therapy in breast cancer			
13:00 13:45	Emanuela Romano Institut Curie - FR	Radiation Therapy as an In Situ Vaccine: Applications in Breast Cancer.	Amphithéâtre Hélène Martel Massignac (BDD)
13:45 14:45	Eric Deutsch Institut Gustave Roussy - FR	Preclinical data and clinical developments of immunotherapy in association with radiation therapy.	
14:45 15:30	Discussion : all participants	Is the time ripe to associate immunotherapy with radiation therapy?	
15:30 16:00	BREAK		BDD HALL
Other novel associations in breast cancer			
16:00 16:15	Philip Poortmans Institut Curie - FR	Hyperthermia and radiation therapy.	Amphithéâtre Hélène Martel Massignac (BDD)
16:15 16:30	Marie Dutreix Institut Curie - FR	Dbait and radiation therapy: preclinical and early clinical developments.	
16:30 17:00	Orit Kaidar-Person Technion Israel Institute of Technology - IL	Tumour Treating Fields and radiation therapy: current clinical applications and possible extension to breast cancer.	
17:00 17:30	Final discussion and closing remarks		